INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- New 36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent and ...

Trulicity is a prescription drug used to manage blood sugar and lower risk of heart problems in people with type 2 diabetes. Learn about its dosages and more.

AWARD-4 was a 52-week randomized, open-label comparator study (double-blind with respect to Trulicity dose assignment) evaluating the effects of Trulicity 1.5 mg (N=295; baseline A1C 8.5%) or 0.75 ...

Food and Drug Administration today approved two additional doses of Eli Lilly and Company's Trulicity ®. "The FDA's decision to approve the additional doses of Trulicity is a positive step ...

INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of ...

Trulicity, which is used in people with type 2 diabetes, can cause certain side effects. Learn about its mild and serious side effects and how to manage them.

Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes ...

Eli Lilly has revealed that it has now received approval from the U.S. Food and Drug Administration (FDA) for two additional doses of Trulicity (dulaglutide). Shares of Eli Lilly closed 1.3% ...

Medically reviewed by Lindsay Cook, PharmD Trulicity (dulaglutide) and Ozempic (semaglutide) are medications classified as glucagon-like peptide 1 (GLP-1) agonists used for the management of type ...

People with diabetes who take injectable medications like Trulicity and Ozempic have been scrambling to find their next dose. Erie-area pharmacies, like others across the country, can't get enough ...

FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for ...